91
|
387
|
3tprA |
Crystal structure of bace1 complexed with an inhibitor |
89
|
392
|
3tplA |
Apo structure of bace1 |
86
|
339
|
3tneA |
The crystal structure of protease sapp1p from candida parapsilosis in complex with the hiv protease inhibitor ritonavir |
102
|
390
|
3tppA |
Crystal structure of bace1 complexed with an inhibitor |
88
|
330
|
3t7xA |
Endothiapepsin in complex with an inhibitor based on the gewald reaction |
84
|
330
|
3t7pA |
Endothiapepsin in complex with a hydrazide derivative |
86
|
330
|
3t7qA |
Endothiapepsin in complex with an inhibitor based on the gewald reaction |
89
|
330
|
3t6iA |
Endothiapepsin in complex with an azepin derivative |
97
|
387
|
3skfA |
Crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with (2s)-2-((3s)-3-(acetylamino)-3-(butan-2-yl)-2-oxopyrrolidin-1-yl)-n-((2s,3r)-3-hydroxy-4-((3-methoxybenzyl)amino)-1-phenylbutan-2-yl)-4-phenylbutanamide |
86
|
386
|
3skgA |
Crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with (2s)-2-((3r)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-n-((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3-isoquinolinyl)ethyl)-4-phenylbutanamide |
88
|
340
|
3sfcA |
Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors |
99
|
387
|
3s7mA |
Pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors |
102
|
387
|
3s7lA |
Pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors |
88
|
387
|
3s2oA |
Fragment based discovery and optimisation of bace-1 inhibitors |
90
|
387
|
3rviA |
Structure of bace-1 (beta-secretase) in complex with 2-((2-amino-6-o-tolylquinolin-3-yl)methyl)-n-(cyclohexylmethyl)pentanamide |
88
|
387
|
3ru1A |
Structure of bace-1 (beta-secretase) in complex with 3-(2-aminoquinolin-3-yl)-n-(cyclohexylmethyl)propanamide |
91
|
387
|
3rtmA |
Structure of bace-1 (beta-secretase) in complex with 3-(2-aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide |
88
|
387
|
3rsvA |
Structure of bace-1 (beta-secretase) in complex with (r)-3-(2-amino-6-o-tolylquinolin-3-yl)-n-((r)-2,2-dimethyltetrahydro-2h-pyran-4-yl)-2-methylpropanamide |
94
|
387
|
3rsxA |
Structure of bace-1 (beta-secretase) in complex with 6-(thiophen-3-yl)quinolin-2-amine |
90
|
387
|
3rthA |
Structure of bace-1 (beta-secretase) in complex with 6-(2-(3,3-dimethylbut-1-ynyl)phenyl)quinolin-2-amine |
92
|
387
|
3rtnA |
Structure of bace-1 (beta-secretase) in complex with 3-(2-amino-6-o-tolylquinolin-3-yl)-n-cyclohexylpropanamide |
84
|
330
|
3lzyA |
Crystal structure of endothiapesin in complex with xenon |
78
|
329
|
2vs2A |
Neutron diffraction structure of endothiapepsin in complex with a gem- diol inhibitor. |
87
|
337
|
5vrpA |
Crystal structure of human renin in complex with a biphenylpipderidinylcarbinol |
88
|
337
|
5vpmA |
Crystal structure of human renin in complex with a biphenylpipderidinylcarbinol |
91
|
337
|
5v8vA |
Crystal structure of human renin in complex with a biphenylpipderidinylcarbinol |
100
|
387
|
5v0nA |
Bace1 in complex with inhibitor 5g |
80
|
343
|
5ux4A |
Crystal structure of rat cathepsin d with (5s)-3-(5,6-dihydro-2h-pyran-3-yl)-1-fluoro- 7-(2-fluoropyridin-3-yl)spiro[chromeno[2,3- c]pyridine-5,4'-[1,3]oxazol]-2'-amine |
87
|
337
|
5tmgA |
Optimization of 3,5-disubstitued piperidine: discovery of non-peptide mimetics as an orally active renin inhibitor |
88
|
337
|
5tmkA |
Optimization of 3,5-disubstitued piperidine: discovery of non-peptide mimetics as an orally active renin inhibitor |
91
|
389
|
5tolA |
Crystal structure of beta-site app-cleaving enzyme 1 complexed with n-(3-((4as,7as)-2-amino-4,4a,5,6-tetrahydro-7ah-furo[2,3-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-bromo-2-pyridinecarboxamide |
100
|
389
|
5t1uA |
Aminomethyl-derived beta secretase (bace1) inhibitors: engaging gly230 without an anilide functionality |
82
|
339
|
5t4sA |
Novel approach of fragment-based lead discovery applied to renin inhibitors |
86
|
339
|
5sy2A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
103
|
389
|
5t1wA |
Aminomethyl-derived beta secretase (bace1) inhibitors: engaging gly230 without an anilide functionality |
89
|
337
|
5sy3A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
87
|
337
|
5sz9A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
82
|
330
|
5p22A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 120 |
83
|
330
|
5p1yA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 117 |
82
|
330
|
5p8jA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 352 |
84
|
330
|
5p3aA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 163 |
84
|
330
|
5p5tA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 254 |
83
|
330
|
5p7cA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 309 |
84
|
330
|
5p77A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 304 |
84
|
330
|
5p3rA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 180 |
82
|
330
|
5p8cA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 345 |
83
|
330
|
5p4fA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 204 |
84
|
330
|
5p5sA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 253 |
83
|
330
|
5p11A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 84 |
83
|
330
|
5p6iA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 279 |